CST, 76381P, TREM2 (E9U8L) Rabbit Monoclonal Antibody (Amino-terminal Antigen) (Biotinylated)

Monoclonal Antibody for studying TREM2. Validated for Peptide ELISA (DELFIA). Highly specific and rigorously validated in-house, TREM2 (E9U8L) Rabbit Monoclonal Antibody (Amino-terminal Antigen) (Biotinylated) (CST #76381) is ready to ship. Product Usage Information Biotinylated antibodies are ideal for immunoassay technologies and high-throughput ELISA platforms that require antibody pairs where both antibodies are from the same host. Platforms utilizing biotinylated antibodies include, but are not limited to, MSD, xMAP, Quanterix Simoa, AlphaLISA, AlphaScreen, HTRF, LANCE, and TR-FRET. Optimal dilutions/working concentrations should be determined by the end user. Please contact us if you require the antibody clone biotinylated at a different concentration, a carrier-free formulation, or a more customized packaging solution. Storage Supplied in 140 mM NaCl, 3 mM KCl, 10 mM sodium phosphate (pH 7.4) dibasic, 2 mM potassium phosphate monobasic, 2 mg/mL BSA, and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Specificity / Sensitivity TREM2 (E9U8L) Rabbit Monoclonal Antibody (Amino-terminal Antigen) (Biotinylated) recognizes endogenous levels of total TREM2 protein. This protein does not cross-react with mouse TREM2. A non-specific band of unknown origin is observed migrating at ~75 kDa. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human TREM2 protein. Background The triggering receptor expressed on myeloid cells 2 (TREM2) protein is an innate immune receptor that is expressed on the cell surface of microglia, macrophages, osteoclasts, and immature dendritic cells (1). The TREM2 receptor is a single-pass type I membrane glycoprotein that consists of an extracellular immunoglobulin-like domain, a transmembrane domain, and a cytoplasmic tail. TREM2 interacts with the tyrosine kinase-binding protein DAP12 to form a receptor-signaling complex (2). The TREM2 protein plays a role in innate immunity and a rare functional variant (R47H) of TREM2 is associated with the late-onset risk of Alzheimer's disease (1,3). Research studies using mouse models of Alzheimer's disease indicate that deficiency and haploinsufficiency of TREM2 can lead to increased β-amyloid (Aβ) accumulation as a result of dysfunctional microglial response (4). These results agree with the distribution of TREM2 in human brain regions (e.g., white matter, the hippocampus, and neocortex) that are involved in Alzheimer's disease pathology (2). In addition, amyloid plaque formation induces expression of TREM2 and amyloid phagocytosis (5). Loss-of-function mutations in the corresponding or genes can result in Nasu-Hakola disease, a rare form of progressive presenile dementia that results from polycystic osseous lesions (6). TREM2 membrane shedding occurs by cleavage at the extracellular site between H157/S158, generating an N-terminal shedded fragment and a membrane bound C-terminal fragment (7,8).t Alternate Names PLOSL2; TREM-2; TREM2; Trem2a; Trem2b; Trem2c; Triggering receptor expressed on monocytes 2; Triggering receptor expressed on myeloid cells 2; triggering receptor expressed on myeloid cells 2a Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 28 Source/Isotype: Rabbit IgG